Endothelin receptor antagonists: Potential in Alzheimer's disease

Pharmacological Research

Volumn 63, Issue 6, 2011, Pages 525-531

  Palmer, Jennifer ^a   Love, Seth ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Alzheimer's disease; Beta amyloid; Cerebral blood flow; Endothelin; Endothelin converting enzyme 2

Indexed keywords

ADENOVIRUS VECTOR; ALZHEIMER DISEASE VACCINE; AMBRISENTAN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BOSENTAN; CHOLINESTERASE INHIBITOR; DARUSENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN CONVERTING ENZYME 2; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; GLUTAMATE RECEPTOR ANTAGONIST; METALLOPROTEINASE; PLACEBO; SITAXSENTAN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BRAIN BLOOD FLOW; BRAIN BLOOD VESSEL; CEREBROVASCULAR DISEASE; CLINICAL EFFECTIVENESS; DEMENTIA; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REVIEW; RISK ASSESSMENT; VIRAL GENE DELIVERY SYSTEM;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; BRAIN; HUMANS; METALLOENDOPEPTIDASES; RECEPTORS, ENDOTHELIN;

EID: 79958027318     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2010.12.008     Document Type: Review

References (167)

1. Burns A, Byrne EJ, Maurer K. Alzheimer's disease. Lancet 2002;360:163-5. (Pubitemid 34786210)
2. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M. Alzheimer's disease I. Global prevalence of dementia: a delphi consensus study. Lancet 2005;366:2112-7.
3. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of alzheimer's disease. Alzheimer's Dement 2007;3:186-91. (Pubitemid 46825511)
4. Smith AD. Imaging the progression of alzheimer pathology through the brain. Proc Natl Acad Sci U S A 2002;99:4135-7. (Pubitemid 34285951)
5. Duyckaerts C, Hauw JJ, Piette F, Rainsard C, Poulain V, Berthaux P, Escourolle R. Cortical atrophy in senile dementia of the alzheimer type is mainly due to a decrease in cortical length. Acta Neuropathol (Berl) 1985;66:72-4. (Pubitemid 15138012)
6. Lerch JP, Pruessner J, Zijdenbos AP, Collins DL, Teipel SJ, Hampel H, Evans AC. Automated cortical thickness measurements from mri can accurately separate alzheimer's patients from normal elderly controls. Neurobiol Aging 2008;29:23-30. (Pubitemid 350110605)
7. Terry RD, Peck A, Deteresa R, Schechter R, Horoupian DS. Some morphometric aspects of the brain in senile dementia of the alzheimer type. Ann Neurol 1981;10:184-92. (Pubitemid 11053105)
8. Bobinski M, Wegiel J, Wisniewski HM, Tarnawski M, Reisberg B, DeLeon MJ, Miller DC. Neurofibrillary pathology - correlation with hippocampal formation atrophy in alzheimer disease. Neurobiol Aging 1996;17:909-19. (Pubitemid 27022745)
9. Rapoport SI. In vivo pet imaging and postmortem studies suggest potentially reversible and irreversible stages of brain metabolic failure in alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 1999;249:46-55.
10. Terry RD, Masliah E, Salmon DP, Butters N, Deteresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in alzheimers-disease - synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991;30:572-80.
11. Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW, Morris JC. Altered expression of synaptic proteins occurs early during progression of alzheimer's disease. Neurology 2001;56:127-9. (Pubitemid 32059669)
12. Masliah E, Mallory M, Hansen L, Richard D, Alford M, Terry R. Synaptic and neuritic alterations during the progression of alzheimer's disease. Neurosci Lett 1994;174:67-72. (Pubitemid 24205235)
13. Braak H, Braak E. Neuropathological staging of alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239-59.
14. Love S. Contribution of cerebral amyloid angiopathy to alzheimer's disease. J Neurol Neurosurg Psychiatry 2004;75:1-4. (Pubitemid 38091257)
15. Montalto MC, Farrar G, Hehir CT. Fibrillar and oligomeric β-amyloid as distinct local biomarkers for alzheimer's disease. Ann N Y Acad Sci 2007;1097:239-58. (Pubitemid 47084898)
16. Crystal H, Dickson D, Fuld P, Masur D, Scott R, Mehler M, Masdeu J, Kawas C, Aronson M, Wolfson L. Clinicopathologic studies in dementia - nondemented subjects with pathologically confirmed alzheimers-disease. Neurology 1988;38:1682-7. (Pubitemid 18265029)
17. Glabe CG. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging 2006;27:570-5. (Pubitemid 43290525)
18. Dahlgren KN, Manelli AM, Stine WB, Baker LK, Krafft GA, LaDu MJ. Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability. J Biol Chem 2002;277:32046-53. (Pubitemid 34969015)
19. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006;440:352-7.
20. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol-Lond 2006;572:477-92.
21. Shankar GM, Li SM, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-β protein dimers isolated directly from alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008;14:837-42.
22. van Helmond Z, Heesom K, Love S. Characterisation of two antibodies to oligomeric aβ and their use in elisas on human brain tissue homogenates. J Neurosci Methods 2009;176:206-12.
23. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J. Soluble amyloid-β peptide concentration as a predictor of synaptic change in alzheimer's disease. Am J Pathol 1999;155:853-62. (Pubitemid 29426831)
24. Kuo YM, Emmerling MR, VigoPelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ, Roher AE. Water-soluble aβ (n-40, n-42) oligomers in normal and alzheimer disease brains. J Biol Chem 1996;271:4077-81.
25. Wang J, Dickson DW, Trojanowski JQ, Lee VMY. The levels of soluble versus insoluble brain aβ distinguish alzheimer's disease from normal and pathologic aging. Exp Neurol 1999;158:328-37. (Pubitemid 29382824)
26. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. Soluble pool of aβ amyloid as a determinant of severity of neurodegeneration in alzheimer's disease. Ann Neurol 1999;46:860-6.
27. Gong YS, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL. Alzheimer's disease-affected brain: presence of oligomeric aβ ligands (addls) suggests amolecular basis for reversible memory loss. Proc Natl Acad Sci U S A 2003;100:10417-22. (Pubitemid 37071893)
28. Piccini A, Russo C, Gliozzi A, Relini A, Vitali A, Borghi R, Giliberto L, Armirotti A, D'Arrigo C, Bachi A, Cattaneo A, Canale C, Torrassa S, Saido TC, Markesbery W, Gambetti P, Tabaton M. B-amyloid is different in normal aging and in alzheimer disease. J Biol Chem 2005;280:34186-92. (Pubitemid 41443143)
29. Pearson HA, Peers C. Physiological roles for amyloid beta peptides. J Physiol-Lond 2006;575:5-10.
30. Tanzi RE, Bertram L. Twenty years of the alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005;120:545-55.
31. Li R, Lindholm K, Yang LB, Yue X, Citron M, Yao RQ, Beach T, Sue L, Sabbagh M, Cai HB, Wong P, Price D, Shen Y. Amyloid β peptide load is correlated with increased β-secretase activity in sporadic alzheimer's disease patients. Proc Natl Acad Sci U S A 2004;101:3632-7. (Pubitemid 38338246)
32. Yang LB, Lindholm K, Yan RQ, Citron M, Xia WM, Yang XL, Beach T, Sue L, Wong P, Price D, Li R, Shen Y. Elevated β-secretase expression and enzymatic activity detected in sporadic alzheimer disease. Nat Med 2003;9:3-4. (Pubitemid 36098241)
33. Tyler SJ, Dawbarn D, Wilcock GK, Allen SJ. A- and β-secretase: profound changes in alzheimer's disease. Biochem Biophys Res Commun 2002;299:373-6. (Pubitemid 35365637)
34. Zhao J, Fu YF, Yasvoina M, Shao PZ, Hitt B, O'Connor T, Logan S, Maus E, Citron M, Berry R, Binder L, Vassar R. B-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for alzheimer's disease pathogenesis. J Neurosci 2007;27:3639-49. (Pubitemid 46557686)
35. Preston SD, Steart PV, Wilkinson A, Nicoll JAR, Weller RO. Capillary and arterial cerebral amyloid angiopathy in alzheimer's disease: defining the perivascular route for the elimination of amyloid β from the human brain. Neuropathol Appl Neurobiol 2003;29:106-17. (Pubitemid 36408329)
36. Weller RO, Massey A, Newman TA, Hutchings M, Kuo YM, Roher AE. Cerebral amyloid angiopathy - amyloid-β accumulates in putative interstitial fluid drainage pathways in alzheimer's disease. Am J Pathol 1998;153:725-33. (Pubitemid 28419027)
37. Lam FC, Liu RH, Lu PH, Shapiro AB, Renoir JM, Sharom FJ, Reiner PB. B-amyloid efflux mediated by p-glycoprotein. J Neurochem 2001;76:1121-8.
38. 1-40 peptide from brain by ldl receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000;106:1489-99.
39. Eckman EA, Eckman CB. Aβ-degrading enzymes: modulators of alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem Soc Trans 2005;33:1101-5. (Pubitemid 41659123)
40. Jacobsen JS, Comery TA, Martone RL, Elokdah H, Crandall DL, Oganesian A, Aschmies S, Kirksey Y, Gonzales C, Xu J, Zhou H, Atchison K, Wagner E, Zaleska MM, Das I, Arias RL, Bard J, Riddell D, Gardell SJ, Abou-Gharbia M, Robichaud A, Magolda R, Vlasuk GP, Bjornsson T, Reinhart PH, Pangalos MN. Enhanced clearance of aβ in brain by sustaining the plasmin proteolysis cascade. Proc Natl Acad Sci U S A 2008;105:8754-9. (Pubitemid 351987752)
41. Jiang Q, Lee CYD, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE. Apoe promotes the proteolytic degradation of aβ. Neuron 2008;58:681-93.
42. van Lieshout JJ, Wieling W, Karemaker JM, Secher NH. Syncope, cerebral perfusion, and oxygenation. J Appl Physiol 2003;94:833-48. (Pubitemid 36231994)
43. Cipolla MJ. Cerebrovascular function in pregnancy and eclampsia. Hypertension 2007;50:14-24. (Pubitemid 46986001)
44. Hill MA, Sun Z, Martinez-Lemus L, Meininger GA. New technologies for dissecting the arteriolar myogenic response. Trends Pharmacol Sci 2007;28:308-15. (Pubitemid 47016684)
45. Bayliss WM. On the local reactions of the arterial wall to changes of internal pressure. J Physiol-Lond 1902;28:220-31.
46. Iadecola C, Nedergaard M. Glial regulation of the cerebral microvasculature. Nat Neurosci 2007;10:1369-76. (Pubitemid 350014688)
47. Cox SB, Woolsey TA, Rovainen CM. Localized dynamic changes in cortical blood-flow with whisker stimulation corresponds to matched vascular and neuronal architecture of rat barrels. J Cereb Blood Flow Metab 1993;13:899-913. (Pubitemid 23312637)
48. Ngai AC, Ko KR, Morii S, Winn HR. Effect of sciatic-nerve stimulation on pial arterioles in rats. Am J Physiol 1988;254:H133-9.
49. Silva AC, Lee SP, Iadecola C, Kim SG. Early temporal characteristics of cerebral blood flow and deoxyhemoglobin changes during somatosensory stimulation. J Cereb Blood Flow Metab 2000;20:201-6. (Pubitemid 30019846)
50. Iadecola C. Neurovascular regulation in the normal brain and in alzheimer's disease. Nat Rev Neurosci 2004;5:347-60. (Pubitemid 38568496)
51. Freund TF. Interneuron diversity series: rhythm and mood in perisomatic inhibition. Trends Neurosci 2003;26:489-95. (Pubitemid 37025787)
52. Yang G, Chen G, Ebner TJ, Iadecola C. Nitric oxide is the predominant mediator of cerebellar hyperemia during somatosensory activation in rats. Am J Physiol-Regul Integr Comp Physiol 1999;277:R1760-70.
53. Yang G, Zhang Y, Ross ME, Iadecola C. Attenuation of activity-induced increases in cerebellar blood flow in mice lacking neuronal nitric oxide synthase. Am J Physiol-Heart Circul Physiol 2003;285:H298-304.
54. Yang G, Huard JMT, Beitz AJ, Ross ME, Iadecola C. Stellate neurons mediate functional hyperemia in the cerebellar molecular layer. J Neurosci 2000;20:6968-73.
55. de la Torre JC. Is alzheimer's disease preceded by neurodegeneration or cerebral hypoperfusion? Ann Neurol 2005;57:783-4.
56. Jagust WJ. Neuroimaging in dementia. Neurol Clin 2000;18:885-901. (Pubitemid 32042601)
57. Sharp P, Gemmell H, Cherryman G, Besson J, Crawford J, Smith F. Application of i-123 labeled isopropylamphetamine imaging to the study of dementia. J Nucl Med 1986;27:761-8. (Pubitemid 17022662)
58. Jagust WJ, Budinger TF, Reed BR. The diagnosis of dementia with single photon-emission computed-tomography. Arch Neurol 1987;44:258-62. (Pubitemid 17031601)
59. Pakrasi S, O'Brien JT. Emission tomography in dementia. Nucl Med Commun 2005;26:189-96. (Pubitemid 40411042)
60. Schuff N, Matsumoto S, Kmiecik J, Studholme C, Du A, Ezekiel F, Miller BL, Kramer JH, Jagust WJ, Chui HC, Weiner MW. Cerebral blood flow in ischemic vascular dementia and alzheimer's disease, measured by arterial spin-labeling magnetic resonance imaging. Alzheimer's Dement 2009;5:454-62.
61. O'Brien JT. Role of imaging techniques in the diagnosis of dementia. Br J Radiol 2007;80:S71-77.
62. Dekosky ST, Shih WJ, Schmitt FA, Coupal J, Kirkpatrick C. Assessing utility of single photon emission computed tomography spect scan in alzheimer disease correlation with cognitive severity. Alzheimer Dis Assoc Disord 1990;4:14-23. (Pubitemid 20311746)
63. Imran MB, Kawashima R, Awata S, Sato K, Kinomura S, Ono S, Sato M, Fukuda H. Tc-99m hmpao spect in the evaluation of alzheimer's disease: correlation between neuropsychiatric evaluation and cbf images. J Neurol Neurosurg Psychiatry 1999;66:228-32. (Pubitemid 29103528)
64. Shiraishi H, Chang CC, Kanno H, Yamamoto I. The relationship between cerebral blood flow and cognitive function in patients with brain insult of various etiology. J Clin Neurosci 2004;11:138-41. (Pubitemid 38248411)
65. Qiu CX, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005;4:487-99. (Pubitemid 40982459)
66. Skoog I, Gustafson D. Update on hypertension and alzheimer's disease. Neurol Res 2006;28:605-11. (Pubitemid 44444422)
67. Bellew KM, Pigeon JG, Stang PE, Fleischman W, Gardner RM, Baker WW. Hypertension and the rate of cognitive decline in patients with dementia of the alzheimer type. Alzheimer Dis Assoc Disord 2004;18:208-13.
68. Petrovitch H, White LR, Izmirilian G, Ross GW, Havlik RJ, Markesbery W, Nelson J, Davis DG, Hardman J, Foley DJ, Launer LJ. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the haas. Neurobiol Aging 2000;21:57-62. (Pubitemid 30224786)
69. Sparks DL, Scheff SW, Liu HC, Landers TM, Coyne CM, Hunsaker JC. Increased incidence of neurofibrillary tangles (nft) in nondemented individuals with hypertension. J Neurol Sci 1995;131:162-9.
70. Korf ESC, White LR, Scheltens P, Launer LJ. Midlife blood pressure and the risk of hippocampal atrophy - the honolulu asia aging study. Hypertension 2004;44:29-34. (Pubitemid 38823483)
71. den Heijer T, Launer LJ, Prins ND, van Dijk EJ, Vermeer SE, Hofman A, Koudstaal PJ, Breteler MMB. Association between blood pressure, white matter lesions, and atrophy of the medial temporal lobe. Neurology 2005;64:263-7.
72. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissien A. Midlife vascular risk factors and alzheimer's disease in later life: longitudinal, population based study. Br Med J 2001;322:1447-51. (Pubitemid 32575406)
73. Dickstein DL, Walsh J, Brautigam H, Stockton SD, Gandy S, Hof PR. Role of vascular risk factors and vascular dysfunction in alzheimer's disease. Mt Sinai J Med 2010;77:82-102.
74. Ott A, Stolk RP, van Harskamp F, Pols HAP, Hofman A, Breteler MMB. Diabetes mellitus and the risk of dementia - the rotterdam study. Neurology 1999;53:1937-42.
75. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of alzheimer disease - the nun study. JAMA-J Am Med Assoc 1997;277:813-7.
76. Ruitenberg A, Heijer Td, Bakker SLM, Swieten JCv, Koudstaal PJ, Hofman A, Breteler MMB. Cerebral hypoperfusion and clinical onset of dementia: the rotterdam study. Ann Neurol 2005;57:789-94. (Pubitemid 40798616)
77. Buee L, Hof PR, Bouras C, Delacourte A, Perl DP, Morrison JH, Fillit HM. Pathological alterations of the cerebral microvasculature in alzheimers-disease and related dementing disorders. Acta Neuropathol (Berl) 1994;87:469-80. (Pubitemid 24128974)
78. Iadecola C, Zhang FY, Niwa K, Eckman C, Turner SK, Fischer E, Younkin S, Borchelt DR, Hsiao KK, Carlson GA. Sod1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat Neurosci 1999;2:157-61.
79. Niwa K, Kazama K, Younkin L, Younkin SG, Carlson GA, Iadecola C. Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am J Physiol-Heart Circul Physiol 2002;283:H315-23.
80. Niwa K, Kazama K, Younkin SG, Carlson GA, Iadecola C. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol Dis 2002;9:61-8.
81. Reivich M. Blood flow metabolism couple in brain. Res Publ Assoc Res Nerv Ment Dis 1974;53:125-40.
82. Sokoloff L, Reivich M, Kennedy C, Desrosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M. Deoxyglucose-c-14 method for measurement of local cerebral glucose-utilization - theory, procedure, and normal values in conscious and anesthetized albino-rat. J Neurochem 1977;28:897-916. (Pubitemid 8098854)
83. Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment - can fdg-pet predict who is to rapidly convert to alzheimer's disease? Neurology 2003;60:1374-7.
84. Jagust W, Gitcho A, Sun F, Kuczynski B, Mungas D, Haan M. Brain imaging evidence of preclinical alzheimer's disease in normal aging. Ann Neurol 2006;59:673-81.
85. Silverman DHS, Small GW, Chang CY, Lu CS, de Aburto MAK, Chen W, Czernin J, Rapoport SI, Pietrini P, Alexander GE, Schapiro MB, Jagust WJ, Hoffman JM, Welsh-Bohmer KA, Alavi A, Clark CM, Salmon E, de Leon MJ, Mielke R, Cummings JL, Kowell AP, Gambhir SS, Hoh CK, Phelps ME. Positron emission tomography in evaluation of dementia - regional brain metabolism and long-term outcome. JAMA-J Am Med Assoc 2001;286:2120-7. (Pubitemid 34041597)
86. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early alzheimer's disease. Ann Neurol 1997;42:85-94. (Pubitemid 27304784)
87. Herholz K. Pet studies in dementia. Ann Nucl Med 2003;17:79-89. (Pubitemid 36693059)
88. Jagust W, Reed B, Mungas D, Ellis W, DeCarli C. What does fluorodeoxyglucose pet imaging add to a clinical diagnosis of dementia? Neurology 2007;69:871-7.
89. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang FS, Cole G. Correlative memory deficits, aβ elevation, and amyloid plaques in transgenic mice. Science 1996;274:99-102. (Pubitemid 26332733)
90. Hsiao KK, Borchelt DR, Olson K, Johannsdottir R, Kitt C, Yunis W, Xu S, Eckman C, Younkin S, Price D, Iadecola C, Clark HB, Carlson G. Age-related cns disorder and early death in transgenic fvb/n mice overexpressing alzheimer amyloid precursor proteins. Neuron 1995;15:1203-18.
91. Bourasset F, Ouellett M, Tremblay C, Julien C, Do TM, Oddo S, LaFerla F, Calon F. Reduction of the cerebrovascular volume in a transgenic mouse model of alzheimer's disease. Neuropharmacology 2009;56:808-13.
92. Crawford F, Suo ZM, Fang CH, Mullan M. Characteristics of the in vitro vasoactivity of β-amyloid peptides. Exp Neurol 1998;150:159-68. (Pubitemid 28146435)
93. Price JM, Chi XD, Hellermann G, Sutton ET. Physiological levels of β-amyloid induce cerebral vessel dysfunction and reduce endothelial nitric oxide production. Neurol Res 2001;23:506-12. (Pubitemid 32642784)
94. Price JM, Sutton ET, Hellermann A, Thomas T. B-amyloid induces cerebrovascular endothelial dysfunction in the rat brain. Neurol Res 1997;19:534-8. (Pubitemid 27419426)
95. 1-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice. J Cereb Blood Flow Metab 2000;20:1659-68.
96. Niwa K, Porter VA, Kazama K, Cornfield D, Carlson GA, Iadecola C. Aβ-peptides enhance vasoconstriction in cerebral circulation. Am J Physiol-Heart Circul Physiol 2001;281:H2417-24.
97. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M. B-amyloid-mediated vasoactivity and vascular endothelial damage. Nature 1996;380:168-71.
98. Thomas T, McLendon C, Sutton ET, Thomas G. Cerebrovascular endothelial dysfunction mediated by β-amyloid. Neuroreport 1997;8:1387-91. (Pubitemid 27242542)
99. Gentile MT, Vecchione C, Maffei A, Aretini A, Marino G, Poulet R, Capobianco L, Selvetella G, Lembo G. Mechanisms of soluble β-amyloid impairment of endothelial function. J Biol Chem 2004;279:48135-42. (Pubitemid 39540968)
100. Luo F, Seifert TR, Edalji R, Loebbert RW, Hradil VP, Harlan J, Schmidt M, Nimmirich V, Cox BF, Fox GB. Non-invasive characterization of β-amyloid(1-40) vasoactivity by functional magnetic resonance imaging in mice. Neuroscience 2008;155:263-9.
101. Chisari M, Merlo S, Sortino MA, Salomone S. Long-term incubation with β-amyloid peptides impairs endothelium-dependent vasodilatation in isolated rat basilar artery. Pharmacol Res 2010;61:157-61.
102. Dietrich H, Xiang C, Han B, Zipfel G, Holtzman D. Soluble amyloid-β, effect on cerebral arteriolar regulation and vascular cells. Molecular Neurodegeneration 2010;5:15.
103. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol 1986;250:H822-7.
104. Paris D, Parker TA, Town T, Suo ZM, Fang CH, Humphrey J, Crawford F, Mullan M. Role of peroxynitrite in the vasoactive and cytotoxic effects of alzheimer's β-amyloid(1-40) peptide. Exp Neurol 1998;152:116-22.
105. Townsend KP, Obregon D, Quadros A, Patel N, Volmar C, Paris D, Mullan M. Proinflammatory and vasoactive effects of a beta in the cerebrovasculature. Alzheimer's Dis: Vasc Etiol Pathol 2002;977:65-76. (Pubitemid 35418137)
106. Paris D, Town T, Mori T, Parker TA, Humphrey J, Mullan M. Soluble β-amyloid peptides mediate vasoactivity via activation of a pro-inflammatory pathway. Neurobiol Aging 2000;21:183-97. (Pubitemid 30387077)
107. Paris D, Humphrey J, Quadros A, Patel N, Crescentini R, Crawford F, Mullan M. Vasoactive effects of aβ in isolated human cerebrovessels and in a transgenic mouse model of alzheimer's disease: role of inflammation. Neurol Res 2003;25:642-51. (Pubitemid 37087609)
108. Palmer JC, Kehoe PG, Love S. Endothelin-converting enzyme-1 in alzheimer's disease and vascular dementia. Neuropathol Appl Neurobiol 2010;36:487-97.
109. Palmer JC, Baig S, Kehoe PG, Love S. Endothelin-converting enzyme-2 is increased in alzheimer's disease and up-regulated by aβ. Am J Pathol 2009;175:262-70.
110. Emoto N, Yanagisawa M. Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic ph optimum. J Biol Chem 1995;270:15262-8.
111. Eckman EA, Reed DK, Eckman CB. Degradation of the alzheimer's amyloid-β peptide by endothelin-converting enzyme. J Biol Chem 2001;276:24540-8.
112. Yanagisawa H, Hammer RE, Richardson JA, Emoto N, Williams SC, Takeda S, Clouthier DE, Yanagisawa M. Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. J Clin Invest 2000;105:1373-82. (Pubitemid 30322403)
113. Eckman EA, Watson M, Marlow L, Sambamurti K, Eckman CB. Alzheimer's disease β-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J Biol Chem 2003;278:2081-4. (Pubitemid 36801269)
114. Rodriguiz RM, Gadnidze K, Ragnauth A, Dorr N, Yanagisawa M, Wetsel WC, Devi LA. Animals lacking endothelin-converting enzyme-2 are deficient in learning and memory. Genes Brain Behav 2008;7:418-26. (Pubitemid 351590928)
115. Minami M, Kimura M, Iwamoto N, Arai H. Endothelin-1-like immunoreactivity in cerebral-cortex of alzheimer-type dementia. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:509-13.
116. Deane R, Yan SD, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B. Rage mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003;9:907-13. (Pubitemid 36889934)
117. Palmer J, Kehoe P, Love S. Aβ induces endothelin-1 production by sh-sy5y neuroblastoma cells. Brain Pathol 2010;20(suppl 1):18.
118. Palmer J, Kehoe P, Love S. Et-1 is elevated in the brain in ad and its neuronal production and release are upregulated by aβ1-42. Neuropathol Appl Neurobiol 2011;37(Suppl. 1):34.
119. Loesch A. Localisation of endothelin-1 and its receptors in vascular tissue as seen at the electron microscopic level. Curr Vasc Pharmacol 2005;3:381-92. (Pubitemid 41264291)
120. Milner P, Loesch A, Burnstock G. Neural endothelin in hypertension: increased expression in ganglia and nerves to cerebral arteries of the spontaneously hypertensive rat. J Vasc Res 2000;37:39-49. (Pubitemid 30158040)
121. Miners JS, Ashby EL, Baig S, Harrison R, Tayler H, Speedy E, Prince JA, Love S, Kehoe PG. Angiotensin-converting enzyme levels and activity in alzheimer's disease: differences in brain and csf ace and association with ace1 genotypes. Am J Transl Res 2009;1:163-77.
122. Zou K, Maeda T, Watanabe A, Liu J, Liu S, Oba R, Satoh Y-I, Komano H, Michikawa M. Aβ42-to-aβ40-and angiotensin-converting activities in different domains of angiotensin-converting enzyme. J Biol Chem 2009;284:31914-20.
123. Hemming ML, Selkoe DJ. Amyloid β-protein is degraded by cellular angiotensin-converting enzyme (ace) and elevated by an ace inhibitor. J Biol Chem 2005;280:37644-50. (Pubitemid 41642372)
124. Kehoe PG, Miners S, Love S. Angiotensins in alzheimer's disease - friend or foe? Trends Neurosci 2009;32:619-28.
125. Farlow M. A clinical overview of cholinesterase inhibitors in alzheimer's disease. Int Psychogeriatr 2002;14:93-126. (Pubitemid 36206093)
126. Cummings JL. Use of cholinesterase inhibitors in clinical practice - evidence-based recommendations. Am J Geriatr Psychiatry 2003;11:131-45. (Pubitemid 36254187)
127. Birks J. Cholinesterase inhibitors for alzheimer's disease. In: Cochrane Database of Systematic Reviews; 2006.
128. Burns A, O'Brien J. Clinical practice with anti-dementia drugs: a consensus statement from british association for psychopharmacology. J Psychopharmacol (Oxf) 2006;20:732-55. (Pubitemid 44622739)
129. Farlow MR. Utilizing combination therapy in the treatment of alzheimer's disease. Expert Rev Neurother 2004;4:799-808. (Pubitemid 39186685)
130. McShane R, Sastre AA, Minakaran N. Memantine for dementia. In: Cochrane Database of Systematic Reviews; 2006.
131. Farlow MR, Miller ML, Pejovic V. Treatment options in alzheimer's disease: maximizing benefit, managing expectations. Dement Geriatr Cogn Disord 2008;25:408-22. (Pubitemid 351630074)
132. Mondadori CRA, Buchmann A, Mustovic H, Schmidt CF, Boesiger P, Nitsch RM, Hock C, Streffer J, Henke K. Enhanced brain activity may precede the diagnosis of alzheimer's disease by 30 years. Brain 2006;129:2908-22.
133. GomezIsla T, Price JL, McKeel DW, Morris JC, Growdon JH, Hyman BT. Profound loss of layer ii entorhinal cortex neurons occurs in very mild alzheimer's disease. J Neurosci 1996;16:4491-500. (Pubitemid 26243044)
134. Morris JC, Storandt M, McKeel DW, Rubin EH, Price JL, Grant EA, Berg L. Cerebral amyloid deposition and diffuse plaques in "normal" aging: evidence for presymptomatic and very mild alzheimer's disease. Neurology 1996;46:707-19.
135. Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley-Whyte ET, Frosch MP, Albert MS, Hyman BT, Irizarry MC. Early aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in ad brain. Neurology 2004;62:925-31. (Pubitemid 38435780)
136. Boche D, Denham N, Holmes C, Nicoll JAR. Neuropathology after active aβ42 immunotherapy: implications for alzheimer's disease pathogenesis. Acta Neuropathol (Berl) 2010:120.
137. 42 immunisation in alzheimer's disease: follow-up of a randomised, placebo-controlled phase i trial. Lancet 2008;372:216-23.
138. Josephs KA, Whitwell JL, Ahmed Z, Shiung MM, Weigand SD, Knopman DS, Boeve BF, Parisi JE, Petersen RC, Dickson DW, Jack CR. B-amyloid burden is not associated with rates of brain atrophy. Ann Neurol 2008;63:204-12. (Pubitemid 351355299)
139. van Helmond Z, Miners JS, Kehoe PG, Love S. Higher soluble amyloid-β concentration in frontal cortex of young adults than in normal elderly or alzheimer's disease. Brain Pathol 2010:9999.
140. de la Torre JC. Vascular risk factor detection and control may prevent alzheimer's disease. Ageing Res Rev 2010;9:218-25.
141. Sun X, He G, Qing H, Zhou W, Dobie F, Cai F, Staufenbiel M, Huang LE, Song W. Hypoxia facilitates alzheimer's disease pathogenesis by up-regulating bace1 gene expression. Proc Natl Acad Sci U S A 2006;103:18727-32. (Pubitemid 44913478)
142. Zhang X, Zhou K, Wang RS, Cui JK, Lipton SA, Liao FF, Xu HX, Zhang YW. Hypoxia-inducible factor 1 α (hif-1 α)-mediated hypoxia increases bace1 expression and β-amyloid generation. J Biol Chem 2007;282:10873-80. (Pubitemid 47100783)
143. De Jong GI, Farkas E, Stienstra CM, Plass JRM, Keijser JN, de la Torre JC, Luiten PGM. Cerebral hypoperfusion yields capillary damage in the hippocampal ca1 area that correlates with spatial memory impairment. Neuroscience 1999;91:203-10. (Pubitemid 29170459)
144. DeKosky S. Early intervention is key to successful management of alzheimer disease. Alzheimer Dis Assoc Disord 2003;17:S99-104.
145. Jagust W. Molecular neuroimaging in alzheimer's disease. NeuroRx 2004;1:206-12. (Pubitemid 46589352)
146. Barton M. Yanagisawa M. Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol 2008;86:485-98.
147. Wenzel RR, Fleisch M, Shaw S, Noll G, Kaufmann U, Schmitt R, Jones CR, Clozel M, Meier B, Luscher TF. Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation 1998;98:2235-40. (Pubitemid 28533840)
148. Kohan DE. Endothelin, hypertension and chronic kidney disease: new insights. Curr Opin Nephrol Hypertens 2010;19:134-9.
149. Givertz MM, Colucci WS, LeJemtel TH, Gottlieb SS, Hare JM, Slawsky MT, Leier CV, Loh E, Nicklas JM, Lewis BE. Study I. Acute endothelin a receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation 2000;101:2922-7. (Pubitemid 30415882)
150. Kato T, Kassab S, Wilkins FC, Kirchner KA, Keiser J, Granger JP. Endothelin antagonists improve renal-function in spontaneously hypertensive rats. Hypertension 1995;25:883-7.
151. Ohlstein EH, Douglas SA, Ezekiel M, Gellai M. Antihypertensive effects of the endothelin receptor antagonist bq-123 in conscious spontaneously hypertensive rats. J Cardiovasc Pharmacol 1993;22:S321-4.
152. Williamson DJ, Wallman LL, Jones R, Keogh AM, Scroope F, Penny R, Weber
153. Chen SJ, Chen YF, Meng QC, Durand J, Dicarlo VS, Oparil S. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 1995;79:2122-31. (Pubitemid 26010587)
154. Galie N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, Chiossi E, Kusic-Pajic A, Simonneau G. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (early study): a double-blind, randomised controlled trial [see comment]. Lancet 2008;371:2093-100. (Pubitemid 351902178)
155. Barton M. Endothelial dysfunction and atherosclerosis: endothelin receptor antagonists as novel therapeutics. Curr Hypertens Rep 2000;2:84-91.
156. Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ, Webb DJ. Endothelin-a receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-b receptor blockade. Circulation 1998;97:752-6. (Pubitemid 28135337)
157. Elesber AA, Bonetti PO, Woodrum JE, Zhu XY, Lerman LO, Younkin SG, Lerman A. Bosentan preserves endothelial function in mice overexpressing app. Neurobiol Aging 2006;27:446-50. (Pubitemid 43185330)
158. Davie NJ, Schermuly RT, Weissmann N, Grimminger F, Ghofrani HA. The science of endothelin-1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: current understanding and future studies. Eur J Clin Invest 2009;39:38-49.
159. Bates KA, Verdile G, Li QX, Ames D, Hudson P, Masters CL, Martins RN. Clearance mechanisms of alzheimer's amyloid-β peptide: implications for therapeutic design and diagnostic tests. Mol Psychiatry 2009;14:469-86.
160. Nalivaeva NN, Fisk LR, Belyaev ND, Turner AJ. Amyloid-degrading enzymes as therapeutic targets in alzheimer's disease. Curr Alzheimer Res 2008;5:212-24. (Pubitemid 351536346)
161. Carty NC, Nash K, Lee D, Mercer M, Gottschall PE, Meyers C, Muzyczka N, Gordon MN, Morgan D. Adeno-associated viral (aav) serotype 5 vector mediated gene delivery of endothelin-converting enzyme reduces a beta deposits in app + ps1 transgenic mice. Mol Ther 2008;16:1580-6.
162. Nilsson P, Iwata N, Muramatsu S-i, Tjernberg LO, Winblad B, Saido TC. Gene therapy in alzheimer's disease - potential for disease modification. J Cell Mol Med 2010;14:741-57.
163. Zhang FY, Eckman C, Younkin S, Hsiao KK, Iadecola C. Increased susceptibility to ischemic brain damage in transgenic mice overexpressing the amyloid precursor protein. J Neurosci 1997;17:7655-61. (Pubitemid 27426204)
164. Suter OC, Sunthorn T, Kraftsik R, Straubel J, Darekar P, Khalili K, Miklossy J. Cerebral hypoperfusion generates cortical watershed microinfarcts in alzheimer disease. Stroke 2002;33:1986-92. (Pubitemid 34840055)
165. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001;81:741-66. (Pubitemid 32267077)
166. Paton JFR, Dickinson CJ, Mitchell G. Harvey cushing and the regulation of blood pressure in giraffe, rat and man: introducing 'cushing's mechanism'. Exp Physiol 2009;94:11-7.
167. Paton JFR, Waki H, Abdala APL, Dickinson J, Kasparov S. Vascular-brain signaling in hypertension: role of angiotensin ii and nitric oxide. Curr Hypertens Rep 2007;9:242-7. (Pubitemid 46894818)